Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase ...
Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer
SYDNEY, Sept. 13, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019 ANZLF Trans-Tasman Innovation & Growth Awards. The Awards celebrate the innovation, growth and ...
St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
SYDNEY, Sept. 12, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that St Jude Children's Research Hospital has successfully completed the first stage of its ongoing phase I study of Kazia's in...
Australian cancer specialists may hold key to next advancement in ovarian cancer treatment
SYDNEY, Aug. 30, 2017 /PRNewswire/ -- Three leading Australian cancer treatment centres are at the forefront of a drug trial that could see the next major advancement in ovarian cancer therapy. Associate Professor Jim Coward, an oncologist at Icon Cancer Care in South Brisbane, is leading the fi...
GDC-0084 Progress Update: On Track for Phase II Commencement in 2017
SYDNEY, Aug. 22, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc inOcto...
Progress Update on Cantrixil(TM) (TRXE-002-1) Development
SYDNEY, Aug. 7, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Phase I Clinical Trial in Ovarian Cancer Pro...
Novogen Provides Update On Development Of Cantrixil
SYDNEY, May 2, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian canc...
Studies Confirm TRXE-009 Crosses the Blood-brain Barrier
NEW YORK, June 5, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) confirms that a lipid formulation of TRXE-009 dosed intravenously to animals was able to deliver therapeutic concentrations of TRXE-009 to brain tissue. This confirms that the d...
Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells
SYDNEY and SAN DIEGO, May 8, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to...
Australian Studies Confirm Anisina as Potential Important New Weapon Against Melanoma
SYDNEY, April 9, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen (NRT:ASX; NVGN: NASDAQ), today announced that studies conducted at The University of Queensland Diamantina Institute (UQDI) revealed that experimental drug, Anisina, killed melanoma cells irrespective of their muta...
Potential of Anisina to Become Major New Chemotherapy Confirmed by Coda Study
SYDNEY, March 19, 2015 /PRNewswire/ -- Novogen announced on 18th March, 2015 that one of its oncology pipeline drug candidates, Anisina (ATM-3507), has achieved a major milestone in its development, confirming the concept that comprehensive destruction of a cancer cell's cytoskeleton can deliver ...
Sky News, Helen Dalley interviews Dr Graham Kelly
SYDNEY, March 10, 2015 /PRNewswire/ -- Novogen Ltd (ASX: 'NRT'; Nasdaq: 'NVGN')CEO, Dr Graham Kelly, PhD, was interviewed by Sky News', Helen Dalley about the breakthrough brain cancer drug being developed by Novogen. Novogen is an Australian-US drug discovery company focused on the clinical ...